Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4):338-45



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 December;64(4):338-45

DOI: 10.23736/S1824-4785.20.03302-6


lingua: Inglese

IAEA contribution to the development of 64Cu radiopharmaceuticals for theranostic applications

Amir R. JALILIAN 1 , Joao A. OSSO JR 1, Julia VERA-ARAUJO 1, Vijay KUMAR 2, Matthew J. HARRIS 3, Bianca GUTFILEN 4, Brigitte GUÉRIN 5, Hongyu LI 6, Fedor ZHURAVLEV 7, Rubel CHAKRAVARTY 8, Behrouz ALIREZAPOUR 9, Miguel A. ÁVILA-RODRÍGUEZ 10, Irfan U. KHAN 11, Ibrahim ALJAMMAZ 12, Thaer ASSAAD 13, Gert LUURTSEMA 14, Jeff SMITH 15, Adriano DUATTI 16

1 Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna International Center, Vienna, Austria; 2 Westmead Hospital, Westmead, Sydney, Australia; 3 Clarity Pharmaceuticals, Sydney, Australia; 4 Department of Radiology, Federal University of Rio de Janeiro, Laboratório de Marcação de Células e Moléculas (LMCM), Rio de Janeiro, Brazil; 5 Department of Nuclear Medicine and Radiobiology, Centre de Recherche du CHUS (CRCHUS), Centre d’Excellence en Imagerie Médicale (CIMUS), University of Sherbrooke, Sherbrooke, Canada; 6 China Isotope and Radiation Corporation, Beijing, China; 7 Hevesy Laboratory, Technical University of Denmark (DTU HEALTH TECH), Roskilde, Denmark; 8 Division of Radiopharmaceuticals, Bhabha Atomic Research Center, Mumbai, India; 9 Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran; 10 Unit of Cyclotron and Radiopharmaceuticals, Division of Investigation, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico; 11 Division of Cyclotron and Allied Radiopharmaceuticals, Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan; 12 Department of Cyclotron and Radiopharmaceuticals, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 13 Department of Radioisotope, Atomic Energy Commission of Syria (AECS), Damascus, Syria; 14 Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen (UMCG), Groningen, the Netherlands; 15 MU School of Medicine, University of Missouri, Columbia, MO, USA; 16 Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy

Copper-64 is a very attractive radioisotope with unique nuclear properties that allow using it as both a diagnostic and therapeutic agent, thus providing an almost ideal example of a theranostic radionuclide. A characteristic of Cu-64 stems from the intrinsic biological nature of copper ions that play a fundamental role in a large number of cellular processes. Cu-64 is a radionuclide that reflects the natural biochemical pathways of Cu-64 ions, therefore, can be exploited for the detection and therapy of certain malignancies and metabolic diseases. Beside these applications of Cu-64 ions, this radionuclide can be also used for radiolabelling bifunctional chelators carrying a variety of pharmacophores for targeting different biological substrates. These include peptide-based substrates and immunoconjugates as well as small-molecule bioactive moieties. Fueled by the growing interest of Member States (MS) belonging to the International Atomic Energy Agency (IAEA) community, a dedicated Coordinated Research Project (CRP) was initiated in 2016, which recruited thirteen participating MS from four continents. Research activities and collaborations between the participating countries allowed for collection of an impressive series of results, particularly on the production, preclinical evaluation and, in a few cases, clinical evaluation of various 64Cu-radiopharmaceuticals that may have potential impact on future development of the field. Since this CRP was finalized at the beginning of 2020, this short review summarizes outcomes, outputs and results of this project with the purpose to propagate to other MS and to the whole scientific community, some of the most recent achievements on this novel class of theranostic 64Cu-pharmaceuticals.

KEY WORDS: Copper-64; Positron-emission tomography; Cupric chloride; Theranostic nanomedicine; Radiopharmaceuticals; Peptides

inizio pagina